www.streetwisereports.com Open in urlscan Pro
104.21.89.231  Public Scan

Form analysis
3 forms found in the DOM

/pub/htdocs/search

<form action="/pub/htdocs/search" id="g_search-box">
  <input type="hidden" name="ie" value="UTF-8">
  <input type="text" name="q" id="the_big_q" placeholder=" Search Site" tabindex="1">
  <button type="submit" name="sa" id="go_search" value="Search"><img src="/images/icons/magnify44.png" class="searchBtn" alt="search"></button>
</form>

<form data-abide="ajax" novalidate="" id="top_slide_in">
  <p class="swr_news_head" style="font-size: 0.95rem; display: block;">
    <span class="close_this_slider" onclick="temp_close_it()"><span style="padding-left: 2px"><i class="fas fa-times-circle"></i></span></span> Get the Latest Investment Ideas Delivered Straight to Your Inbox.
    <a href="/pub/htdocs/signupnow.html?nl=5,8,3" target="_blank" style="color: #000" class="offerbtn sm_offer_bttn">Subscribe</a>
  </p>
  <div class="form-group" id="url_group">
    <label for="url">URL</label>
    <input type="text" name="url" size="20" id="url" class="form-control">
  </div>
</form>

GET /pub/htdocs/signupnow.html

<form data-abide="" id="RightSideSubscribe" action="/pub/htdocs/signupnow.html" method="GET" target="_blank">
  <h3><span class="fab fa-telegram-plane"></span> Want to read more about <b>Biotechnology / Pharmaceuticals</b> and <b>Medical Devices</b> investment ideas?<br> Get Our Streetwise Reports Newsletter <span class="stressed">Free</span> and be the
    first to know!</h3>
  <input id="subEmail" type="email" name="email" pattern="email" autocomplete="email" placeholder="Enter your email address">
  <div id="cap_htm_sec" style="display: none; margin-bottom: 10px; width: 182px; height: 68px; overflow: hidden"></div>
  <input name="submit" type="submit" id="side_nl_sub_button" value="Sign Me Up" class="offerbtn">
  <input type="hidden" name="nl" value="5">
  <input type="hidden" name="nl" value="8">
  <input type="hidden" name="nl" value="3">
  <input type="hidden" name="nl" value="9">
  <input type="hidden" name="f_name" value="Streetwise Right AD Bar Green">
  <small class="error">A valid email address is required to subscribe</small>
  <div class="form-group" id="url_group">
    <label for="url">URL</label>
    <input type="text" name="url" size="20" id="url" class="form-control">
  </div>
</form>

Text Content

Streetwise Reports
The Gold Report
The Energy Report
The Life Sciences Report
Research Reports
Streetwise Reports
The Gold Report
The Energy Report
The Life Sciences Report
Research Reports


 * Articles
   * Agriculture
   * Alternative - Biofuels
   * Alternative - Cleantech
   * Alternative Energy
   * Base Metals
   * Battery Metals
   * Biotechnology / Pharmaceuticals
   * Cannabis
   * Clean Energy
   * Coal
   * Cobalt / Lithium / Manganese
   * Critical Metals
   * Cryptocurrency / Blockchain
   * Gold
   * Healthcare Services
   * Helium
   * Life Sciences Tools & Diagnostics
   * Medical Devices
   * Oil & Gas - Exploration & Production
   * Oil & Gas - Services
   * PGM - Platinum Group Metals
   * Regenerative Medicine
   * Renewable - Geothermal
   * Renewable - Solar
   * Renewable - Wind
   * Robotics
   * Silver
   * Special Situations
   * Technology
   * Uranium
 * Disclosures

Don't Forget To
Rate This Article    

Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

URL

TICKERS: SVA; SEOVF; XETRA


IS IT NOW TIME TO BUY THIS BIOTECH STOCK?
CONTRIBUTED OPINION

View Important Disclosures for this Article
Close Important Disclosures:

 1. Sernova Corp. has a consulting relationship with Street Smart an affiliate
    of Streetwise Reports. Street Smart Clients pay a monthly consulting fee
    between US$8,000 and US$20,000.
 2. As of the date of this article, officers and/or employees of Streetwise
    Reports LLC (including members of their household) own securities of Sernova
    Corp.
 3. Clive Maund:  I determined which companies would be included in this article
    based on my research and understanding of the sector.
 4. Statements and opinions expressed are the opinions of the author and not of
    Streetwise Reports, Street Smart, or their officers. The author is wholly
    responsible for the accuracy of the statements. Streetwise Reports was not
    paid by the author to publish or syndicate this article. Streetwise Reports
    requires contributing authors to disclose any shareholdings in, or economic
    relationships with, companies that they write about. Any disclosures from
    the author can be found  below. Streetwise Reports relies upon the authors
    to accurately provide this information and Streetwise Reports has no means
    of verifying its accuracy. 
 5.  This article does not constitute investment advice and is not a
    solicitation for any investment. Streetwise Reports does not render general
    or specific investment advice and the information on Streetwise Reports
    should not be considered a recommendation to buy or sell any security. Each
    reader is encouraged to consult with his or her personal financial adviser
    and perform their own comprehensive investment research. By opening this
    page, each reader accepts and agrees to Streetwise Reports' terms of use and
    full legal disclaimer. Streetwise Reports does not endorse or recommend the
    business, products, services or securities of any company. 
 6.  This article does not constitute medical advice. Officers, employees and
    contributors to Streetwise Reports are not licensed medical professionals.
    Readers should always contact their healthcare professionals for medical
    advice.

For additional disclosures, please click here.

Clivemaund.com Disclosures

The above represents the opinion and analysis of Mr. Maund, based on data
available to him, at the time of writing. Mr. Maund's opinions are his own, and
are not a recommendation or an offer to buy or sell securities. As trading and
investing in any financial markets may involve serious risk of loss, Mr. Maund
recommends that you consult with a qualified investment advisor, one licensed by
appropriate regulatory agencies in your legal jurisdiction, and do your own due
diligence and research when making any kind of a transaction with financial
ramifications. Although a qualified and experienced stock market analyst, Clive
Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on
the market and stocks cannot be construed as a recommendation or solicitation to
buy and sell securities.

Biotechnology / PharmaceuticalsMedical Devices



Source: Clive Maund (9/16/24)

Technical Analyst Clive Maund shares his thoughts on Sernova Corp. (SVA:TSX.V;
SEOVF:OTCMKTS; XETRA:PSH) to explain why he believes it is a good stock to
accumulate, between the current price and recent lows.


Streetwise Company Fact Sheet

2024/9/19 18:05:22

(SVA:TSX.V - SEOVF:OTCQB - XETRA:PSH)

TSXSVA:CASVA:CASernova Corp.$0.255CAD0.255CAD0.01(4.08%)43.5kAs of:September 19,
2024 3:37 PM


CHARTINGFULLSCREEN

   
 * SVA:CA
   

Market
   
 * All
 * Market
 * Pre-Market
 * Post-Market

   
 * 1D
 * 5D
 * 1M
 * 3M
 * 6M
 * YTD
 * 1Y
 * 2Y
 * 3Y
 * 5Y
 * 10Y

Daily
   
 * Daily
 * Weekly
 * Monthly

Volume:


FREQUENCY:DAILY

Combination chart with 2 data series.
QuoteMedia Interactive chart.
The chart has 1 X axis displaying Time. Range: 2024-06-18 12:54:12 to 2024-09-20
09:03:48.
The chart has 2 Y axes displaying Price and Volume.

Interactive stock chart provided by quotemediaPriceVolumeJul 2024Aug 2024Sep
20240.201 600k© quotemediaFrequency:DAILY
End of interactive chart.


SERNOVA CORP. (SVA:CA)

$0.2550.01 | 4.08%
Bid: 0.235 x 21500Ask: 0.26 x 5000
September 19, 2024 3:37 PMEDTSeptember 19, 2024Volume: 43,500
CADToronto Stock ExchangeDelayed PriceMarket Closed


DETAILED QUOTE

Last
0.255
$ Chg
0.01
Open
0.25
High
0.255
Bid
0.235
Bid Size
21500
Beta
1.3999
Year High
0.83
Marketcap
77.42m
PB Ratio
19.40
Average Volume (30 Day):
299.89k
Volume
43.50k
% Chg
4.08%
Prev. Close
0.245
Low
0.25
Ask
0.26
Ask Size
5000
VWAP
0.25305
Year Low
0.20
Total Shares
303.61m
Shares Out
303.61m
Escrow Shares
2.47m
Float:
273.84m
Exchange
TSX


Analyst coverage

Rodman & Renshaw — Dr. Tony Butler Raymond James — Michael Freeman Leede
Financial Inc. — Dr. Douglas Loe Leede Jones Gable — Doug Loe H.C. Wainwright &
Co. — Dr. Joseph Pantginis Echelon Capital Markets — Stefan Quenneville Raymond
James — Rahul Sarugaser Research Capital Corporation — Dr. Andre Uddin

Newsletter coverage

Clive Maund — CliveMaund.com Chris Temple — The National Investor

Company News

View Latest News

Streetwise Reports Articles

09/17/2024 - View Article 09/16/2024 - View Article 09/16/2024 - View Article
09/16/2024 - View Article 09/16/2024 - View Article

Analysts, Newsletter Writers & More
Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) is a clinical-stage
biotechnology / medical device company that is developing therapeutic cell
technologies for chronic diseases, including insulin-dependent diabetes, thyroid
disease, and blood disorders that include hemophilia A.

Sernova is currently focused on developing a functional cure for
insulin-dependent diabetes with its lead technology, the Cell Pouch transplant
system, a novel implantable and scalable medical device with immune-protected
therapeutic cells. A key feature of the trademarked Cell Pouch transplant system
is that it protects the therapeutic cells from attack by the immune system.

On implantation, the Cell Pouch forms a natural, vascularized tissue environment
in the body, allowing long-term survival and function of therapeutic cells that
release essential factors that are absent or deficient in patients with certain
chronic diseases. Sernova's Cell Pouch transplant system has demonstrated its
potential to be a functional cure for people with T1D in a continuing Phase 1/2
clinical study at the University of Chicago.

Sernova partnered with Evotec to develop an implantable off-the-shelf iPSC-based
islet replacement therapy. This partnership provides Sernova a potentially
unlimited supply of insulin-producing cells to treat millions of patients with
insulin-dependent diabetes (Type 1 and Type 2). Sernova's development pipeline
that uses its Cell Pouch transplant system also includes: a cell therapy for
hypothyroid disease resulting from thyroid gland removal and an ex vivo
lentiviral Factor VIII gene therapy for hemophilia A.

If Sernova is successful in bringing its functional cure for insulin-dependent
diabetes to the stage where it can go into commercial production, the global
market for it will be massive, and some analyses already have a CA$3.00 target
for the stock.

Whilst Sernova's stock has been in a severe bear market from its start of 2022
peak, technical action in the stock in recent months coupled with major positive
fundamental developments strongly suggest that the stock is about to reverse to
the upside, which is why we are taking an interest in it here.

Amongst recent developments, we have the appointment in mid-July of Jonathan
Rigby as Executive Chairman. Note the use of the phrase "carefully curated
management and board transitions" in this news. I have never encountered this
phrase before, and it must be regarded as a new level of sophistication with
respect to presenting the changes that went on in the nicest possible way.

Mr Rigby went on several weeks later to become CEO of the company. This is
significant for two reasons — he has a track record of turning companies into
success stories, and in addition, as a Type 1 Diabetes sufferer himself, it is
reasonable to assume that he has more than usual motivation to see the company's
diabetes treatment advanced to become commercially successful. 

Also regarded as a positive is that despite an earlier financing being pulled
"due to current market conditions" at that time, a later substantial financing
was not just successful but oversubscribed.

Then, at the 2024 European Association for the Study of Diabetes (EASD) annual
meeting in Madrid, Spain, Sernova announced new positive data from its Phase 1/2
trial regarding islet survival and function, with Sernova's CEO commenting,  "We
believe this first-in-world data is significant for Sernova and, more
specifically, provides tangible hope for T1D patients that we are a significant
step further in our mission of providing a functional cure for this terrible
disease; as a Type 1 diabetic myself, I could not be more determined to drive
our program forward and ultimately onto the market."

So the fundamentals of the company certainly seem to be heading in the right
direction which is a big reason that the stock is considered to be very
undervalued here given its huge potential in this market.

Turning now to the charts and starting with the 5-year chart, we see that
Sernova had a huge spike late in 2020 and early in 2021 that saw it rocket up
from about CA$0.30 to briefly touch CA$2.80. This spike followed a very long
base pattern that had built out for about 12 years.

Following the spike a large top pattern formed through mid-2022 that led to a
breakdown into a severe bear market that continues to this day. The downtrend
has taken the form of a Falling Wedge which shows that selling pressure is
slowly abating, which has bullish implications and as it has now brought the
price down into a zone of strong support in the base pattern that generated the
major spike at a time when the fundamental outlook for the company is rapidly
improving, a reversal to the upside is looking more and more likely soon.



On the year-to-date chart we can see that although the downtrend still remains
in force with moving averages in bearish alignment, there is strong evidence
that a reversal to the upside may be occurring. The persistent heavy volume
since late July is an indication that a bottom may be in, made more likely of
course by the price now being at a low level after prolonged decline with it
currently trying to hold a break above the 50-day moving average with momentum
(MACD) now trending higher and rapidly improving.

Normally we would expect some base building after such a long and deep decline,
but fundamental outlook for the company is improving at such a rate that it may
not tarry long in this area before the stock appreciates significantly, hence
the reason for our interest here.



Sernova is therefore viewed as a good stock to accumulate in this area, between
the current price and recent lows.

Sernova Corp.'s website.

Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) closed for trading at
CA$0.255, US$0.1866 on September 13, 2024.






Want to be the first to know about interesting Biotechnology / Pharmaceuticals
and Medical Devices investment ideas? Sign up to receive the FREE Streetwise
Reports' newsletter. Subscribe



Important Disclosures:

 1. Sernova Corp. has a consulting relationship with Street Smart an affiliate
    of Streetwise Reports. Street Smart Clients pay a monthly consulting fee
    between US$8,000 and US$20,000.
 2. As of the date of this article, officers and/or employees of Streetwise
    Reports LLC (including members of their household) own securities of Sernova
    Corp.
 3. Clive Maund:  I determined which companies would be included in this article
    based on my research and understanding of the sector.
 4. Statements and opinions expressed are the opinions of the author and not of
    Streetwise Reports, Street Smart, or their officers. The author is wholly
    responsible for the accuracy of the statements. Streetwise Reports was not
    paid by the author to publish or syndicate this article. Streetwise Reports
    requires contributing authors to disclose any shareholdings in, or economic
    relationships with, companies that they write about. Any disclosures from
    the author can be found  below. Streetwise Reports relies upon the authors
    to accurately provide this information and Streetwise Reports has no means
    of verifying its accuracy. 
 5.  This article does not constitute investment advice and is not a
    solicitation for any investment. Streetwise Reports does not render general
    or specific investment advice and the information on Streetwise Reports
    should not be considered a recommendation to buy or sell any security. Each
    reader is encouraged to consult with his or her personal financial adviser
    and perform their own comprehensive investment research. By opening this
    page, each reader accepts and agrees to Streetwise Reports' terms of use and
    full legal disclaimer. Streetwise Reports does not endorse or recommend the
    business, products, services or securities of any company. 
 6.  This article does not constitute medical advice. Officers, employees and
    contributors to Streetwise Reports are not licensed medical professionals.
    Readers should always contact their healthcare professionals for medical
    advice.

For additional disclosures, please click here.

Clivemaund.com Disclosures

The above represents the opinion and analysis of Mr. Maund, based on data
available to him, at the time of writing. Mr. Maund's opinions are his own, and
are not a recommendation or an offer to buy or sell securities. As trading and
investing in any financial markets may involve serious risk of loss, Mr. Maund
recommends that you consult with a qualified investment advisor, one licensed by
appropriate regulatory agencies in your legal jurisdiction, and do your own due
diligence and research when making any kind of a transaction with financial
ramifications. Although a qualified and experienced stock market analyst, Clive
Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on
the market and stocks cannot be construed as a recommendation or solicitation to
buy and sell securities.



RELATED ARTICLES

Trial Data Help Position Cell Pouch for Commercial Success
Source: Dr. Joseph Pantginis (09/16/2024)

The upside implied in the target price on this Canadian firm, developing
regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright
& Co. report.

read more >

Implanted Cell Device Reaches 5 Year Milestone
Source: Stefan Quenneville (09/16/2024)

This pouch, loaded with pancreatic islet cells, is being evaluated in patients
with insulin-dependent Type 1 diabetes, noted a Ventum Capital Markets report.

read more >

Co's. Cell Pouch Performs Well in Study
Source: Dr. Douglas Loe (09/16/2024)

Data show the device keeps the incorporated therapeutic cells alive and
functioning for at least five years, noted a Leede Financial Inc. report.

read more >

California Biotech Reports Positive QOL Improvements in Program
Source: Dr. Jonathan Aschoff (09/13/2024)

With Ontrak Inc.'s (OTRK:NASDAQ) significant results from the first six months
of data collected through its implementation of ReQoL, Roth MKM analyst Dr,
Jonathan Schoff gave the company a Buy rating.

read more >

Biotech Co. Says New Data Show Success of Type 1 Diabetes Treatment
Source: Streetwise Reports (09/12/2024)

Clinical stage biotechnology company Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS;
XETRA:PSH) has released new data that show success in using its Cell Pouch
Transplant System to help Type 1 diabetes patients reach insulin independence.
One author says the company is David taking on Goliath in the race for a cure.

read more >





WANT TO READ MORE ABOUT BIOTECHNOLOGY / PHARMACEUTICALS AND MEDICAL DEVICES
INVESTMENT IDEAS?
GET OUR STREETWISE REPORTS NEWSLETTER FREE AND BE THE FIRST TO KNOW!


A valid email address is required to subscribe
URL


RECOMMENDED ARTICLES

Trial Data Help Position Cell Pouch for Commercial Success

Source: Dr. Joseph Pantginis (09/16/2024)



read more >


Implanted Cell Device Reaches 5 Year Milestone

Source: Stefan Quenneville (09/16/2024)



read more >


Co's. Cell Pouch Performs Well in Study

Source: Dr. Douglas Loe (09/16/2024)



read more >


California Biotech Reports Positive QOL Improvements in Program

Source: Dr. Jonathan Aschoff (09/13/2024)



read more >


Biotech Co. Says New Data Show Success of Type 1 Diabetes Treatment

Source: Streetwise Reports (09/12/2024)



read more >



HAVE YOU SIGNED UP FOR OUR NEWSLETTER YET?



No Thanks


 * Subscribe
 * About
 * Disclaimer
 * Contact
 * Sponsorship
 * Syndication
 * Careers
 * Policies



© 2024 Streetwise Reports. All rights reserved.

Streetwise Reports is registered with the U.S. Patent and Trademark Office.